<DOC>
	<DOC>NCT00703703</DOC>
	<brief_summary>This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older</brief_summary>
	<brief_title>Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Healthy males and females â‰¥ 50 years Body mass index equal to or greater than 18.5 kg/m2 and less than 35.0 kg/m2 Known or suspected allergy to tolterodine ER or darifenacin or their components Subjects with irregular day and night patterns such as night shift workers Significant medical problems know to affect heart rate (ie., hypertension, hypotension, history of heart failure, history of pulmonary disease, etc.) Medication with potential known to affect heart rate History of any malignancy within the past 5 years, with the exception of localized basal cell carcinoma of the skin Pregnant or nursing women Subjects with diseases such as urinary retention, gastric retention, uncontrolled narrowangle glaucoma, severe renal insufficiency, etc. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Heart rate, overactive bladder</keyword>
</DOC>